Modular Medical Inc., a pre-revenue medical device company, released its annual report for the fiscal year ending March 31, 2025. The report indicates that the company has not yet generated revenue as it remains focused on the design, development, and commercialization of innovative insulin pumps. The company reported an increase in research and development expenses, rising to $14.697 million in 2025 from $12.880 million in 2024, marking a 14.1% increase year over year. The company continues to navigate challenging market conditions, including the impact of inflation and increased interest rates, which could affect its access to capital markets. There was no specific guidance or outlook regarding future revenues or profitability included in the report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.